[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharming Group N.V. ADR (PHAR)

Pharming Group N.V. ADR (PHAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 811,116
  • Shares Outstanding, K 70,778
  • Annual Sales, $ 376,130 K
  • Annual Income, $ 2,850 K
  • EBIT $ 18 M
  • EBITDA $ 30 M
  • 60-Month Beta -0.01
  • Price/Sales 2.23
  • Price/Cash Flow 59.09
  • Price/Book 3.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.10
  • Number of Estimates 2
  • High Estimate $0.20
  • Low Estimate $0.00
  • Prior Year $0.10
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.62 +22.35%
on 07/30/26
13.32 -11.64%
on 08/13/26
-0.84 (-6.70%)
since 07/24/26
3-Month
9.62 +22.35%
on 07/30/26
14.79 -20.42%
on 07/08/26
-0.83 (-6.59%)
since 05/22/26
52-Week
9.62 +22.35%
on 07/30/26
21.34 -44.85%
on 01/27/26
-2.51 (-17.58%)
since 08/25/25

Most Recent Stories

More News
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.

PHAR : 11.77 (+2.71%)
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. (“Pharming” or the...

PHAR : 11.77 (+2.71%)
Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR ) investors concerning the Company’s possible...

PHAR : 11.77 (+2.71%)
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR ) on behalf of investors concerning the Company’s...

PHAR : 11.77 (+2.71%)
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

Pharming Group missed Q2 2026 consensus revenue estimates and shares dropped 22% in a single session. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors who...

PHAR : 11.77 (+2.71%)
PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group

On May 7, 2026, Pharming Group's CEO reaffirmed full-year revenue guidance of $405 million to $425 million. Twelve weeks later, the Company cut that range to $375 million to $395 million and the stock...

PHAR : 11.77 (+2.71%)
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)

Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and PHAR shares fell 22% the day it was reported. Levi & Korsinsky is investigating potential securities...

PHAR : 11.77 (+2.71%)
Pharming Group Q1 Earnings Call Highlights

Pharming Group (NASDAQ:PHAR) executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company’s planned...

PHAR : 11.77 (+2.71%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised...

PHAR : 11.77 (+2.71%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised...

PHAR : 11.77 (+2.71%)

Business Summary

Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The company's product portfolio includes C1INH. Pharming Group N.V. is based in Leiden, The Netherlands....

See More

Key Turning Points

3rd Resistance Point 12.22
2nd Resistance Point 12.09
1st Resistance Point 11.93
Last Price 11.77
1st Support Level 11.64
2nd Support Level 11.51
3rd Support Level 11.35

See More

52-Week High 21.34
Fibonacci 61.8% 16.86
Fibonacci 50% 15.48
Fibonacci 38.2% 14.10
Last Price 11.77
52-Week Low 9.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.